Navigation Links
Innovative and Forward-Thinking Experts to Deliver Keynote Presentations at IBC's 13th Annual Drug Discovery & Development of Innovative Therapeutics World Congress
Date:5/7/2008

Presenters include David M. Mott from MedImmune Inc., Elliott Sigal, M.D., Ph.D, from Bristol-Myers Squibb Company, Federico Goodsaid, Ph.D from the

FDA, and Mark Ratner from FDC_Windhover

WESTBOROUGH, Mass., May 7 /PRNewswire/ -- IBC Life Sciences announced the keynote line up for the 13th Annual Drug Discovery & Development of Innovative Therapeutics World Congress, to take place August 4-7, 2008 in Boston, MA. The keynote presentations will include speakers David M. Mott from MedImmune Inc. and Elliott Sigal, M.D., Ph.D, from Bristol-Myers Squibb Company. Keynote panel discussions this year will be led by Federico Goodsaid, Ph.D from the FDA, and Mark Ratner from FDC Windhover.

The two individual keynote speakers will discuss the scientific and business strategies that are necessary to move to clinical POC quickly. Keynote panel discussions will approach the more "controversial" topics such as the FDA position on biomarkers and the impact of the 2008 elections on the future of the pharmaceutical/healthcare industry. Presentations include:

4:20 PM, Tuesday, August 5:

Keynote speaker David M. Mott, Chief Executive Officer and President, MedImmune, Inc. will present "Risk-Taking & Innovation in Biotechnology: The MedImmune Success Story."

5:00 PM, Tuesday, August 5:

Keynote panel discussion "Biomarker Qualification in Drug Development: A Regulatory/Industry Discussion" will be led by Federico Goodsaid, Ph.D., Associate Director for Operations in Genomics, Office of Clinical Pharmacology, Office of Translational Sciences, CDER, FDA.

11:20 AM, Wednesday, August 6:

Keynote speaker Elliott Sigal, M.D., Ph.D. Executive Vice President, Chief Scientific Officer and President, Research & Development, Bristol-Myers Squibb Company will discuss "BioPharma of the Future: Blending the Best to Create the Next."

12:00 PM, Wednesday, August 6:

Keynote panel discussion "Leading in a Sea of Change - The Influence of Politics, Change and Innovation on the Future of Pharma/Biotech" will be moderated by Mark Ratner, Contributing Editor, FDC-Windhover.

"Industry experts David Mott and Elliot Sigal being on the program this year will truly bring novel ideas forward," said Michael P. Keenan, Project Manager and Producer, IBC Life Sciences. "In addition, for the first time ever at this event, a tactical FDA Associate Director will discuss the FDA position on biomarkers. And finally, the topic that everyone is thinking about, but never likes to discuss out loud: 'What will the Business and R&D Model of Future 'Big Pharma" Look Like?'' will be among one of the topics addressed in one of our Keynote Panel Discussions."

Complete details on this event can be found at http://www.drugdisc.com or to receive a press pass or arrange an interview with a speaker, email Keri Dostie at kdostie@ibcusa.com.

About IBC Life Sciences

IBC Life Sciences is the worldwide leader in scientific, technological and business conferences and courses for the life science industry. To develop its programs, IBC actively researches the advancements, technologies and trends impacting and driving the race for new drugs and therapies. No other organization can make claim to the breadth and quality that IBC Life Sciences delivers in each event giving the company recognition around the globe for quality, service and value. For more information, visit: http://www.IBCLifeSciences.com .

Contact: Keri Dostie

IBC Life Sciences

508 - 614 - 1404

kdostie@ibcusa.com


'/>"/>
SOURCE IBC Life Sciences
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. New TUMS(R) QuikPak(TM) Campaign Offers Innovative Heartburn Relief with a Little Help from the Jetsons
2. BioSpace and IBC Life Sciences Announce Career Fair Alliance For Drug Discovery & Development of Innovative Therapeutics World Congress
3. Sigma(R) Launches Innovative ChIP Kit Technology For Epigenetic Research
4. Bon MOT: Innovative atom trap catches highly magnetic atoms
5. Monogram HIV Antibody Assay Is Key Component of Innovative Vaccine Development Program
6. Bayer HealthCare Pharmaceuticals Introduces VistaTrak(TM) an Innovative Contrast Media Management System
7. CV Therapeutics and Medlogics Device Corporation Sign Licensing Agreement for CVTs Innovative Stent Coating Technology
8. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
9. A&G Pharmaceutical Receives $870,000 Grant from Avon Foundation to Advance Innovative Blood Diagnostic Test for Early Detection of Breast Cancer
10. Ferndale and Foamix Enter Development of an Innovative Foam for the Treatment of Atopic Dermatitis
11. Innovative Fosshield(R) Antimicrobial Technology Shown to Continuously Kill MRSA Superbug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ANN ARBOR, Mich. , Dec. 7, 2016 ... breakthrough immune modulatory medicines, announced today the initiation of ... therapeutic candidate, LYC-30937- E nteric C oated, in ... disease that is estimated to affect as many as ... , with approximately 1.5 - 3 million cases being ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... ... digital pathology, announced today a new service to enable rapid migration of large ... upload has remained one of the factors limiting adoption of digital pathology. Proscia’s ...
(Date:12/7/2016)... Woods Hole, Massachusetts (PRWEB) , ... December 07, 2016 , ... Kara Dwyer Dodge grew ... 1966, Richard Dwyer, a third-generation fisherman in Scituate, Mass., found a sea turtle entangled in ... to shore, where the turtle became a minor sensation because no one could remember ever ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... privately-held contract pharmaceutical development and manufacturing organisation, today announced the formation ... combining a leading CRO and the industry’s only Contract Commercial Organization (CCO). ...
Breaking Biology Technology:
(Date:11/19/2016)... , Nov. 18, 2016 Securus Technologies, a ... for public safety, investigation, corrections and monitoring, announced today ... competitor, ICSolutions, to have an independent technology judge determine ... most modern high tech/sophisticated telephone calling platform, and the ... that they do most of what we do – ...
(Date:11/15/2016)... , Nov. 15, 2016  Synthetic Biologics, Inc. ... therapeutics focused on the gut microbiome, today announced ... 25,000,000 shares of its common stock and warrants ... at a price to the public of $1.00 ... Synthetic Biologics from the offering, excluding the proceeds, ...
(Date:6/27/2016)... Research and Markets has announced the addition of the ... The report forecasts the biometrics ... a CAGR of 12.28% during the period 2016-2020. ... with inputs from industry experts. The report covers the market landscape ... includes a discussion of the key vendors operating in this market. ...
Breaking Biology News(10 mins):